Search Results

This post kicks off a four-part series on plasma transfusion — starting with the types of plasma products and how they differ. In upcoming posts, we’ll look at common (and not-so-common) indications for plasma, examine where and why plasma is often misused, and explore alternatives to plasma. When someone says “FFP,” they often mean any  kind of plasma product. But not all plasma is created equal — and the distinctions matter. Different processing timelines and storage conditions lead to real differences in coagulation factor content, stability, and shelf life. These variations can impact clinical decisions, especially when patients need rapid hemostasis or factor replacement. Let’s break it down: I. Fresh Frozen Plasma (FFP) FFP is plasma separated and frozen within 8 hours of whole blood collection. It contains the highest levels of labile coagulation factors, especially factor V and factor VIII, which are the most sensitive to degradation during processing and storage. Storage: Up to 1 year at –18°C or colder. After thawing: Can be stored at 1–6°C for up to 24 hours and still labeled "FFP." Beyond that, it is relabeled as thawed plasma. Indications: Replacement of multiple coagulation factors in active bleeding with documented coagulopathy, especially when specific factor levels are unknown. Massive transfusion protocols. Liver disease ONLY IF bleeding is present and the patient has a prolonged PT/aPTT. DIC, again with bleeding and prolonged PT/aPTT. Rarer inherited factor deficiencies (e.g., factor V or XI deficiency) when specific concentrates or recombinant factors are unavailable. Plasma exchange for TTP. II. Plasma Frozen Within 24 Hours (PF24 or FP24) PF24 is plasma that is frozen between 8 and 24 hours after collection. It contains slightly lower levels of factor VIII, and potentially modest reductions in other labile factors, but is still considered hemostatically effective in most clinical contexts. Storage: Up to 1 year at –18°C or colder. After thawing: Stored at 1–6°C for up to 24 hours as "PF24." After that, it becomes thawed plasma, just like true FFP. Indications: Functionally interchangeable with FFP for most transfusion scenarios. Suitable for warfarin reversal when prothrombin complex concentrate (PCC) is unavailable. Can be used in TTP or other plasma exchange protocols. Often preferred for inventory reasons due to longer processing windows and availability. III. Thawed Plasma Thawed plasma refers to FFP or PF24 that has been thawed and stored at 1–6°C for more than 24 hours, up to a maximum of 5 days. After the initial 24 hours, it's no longer considered “fresh” due to degradation of labile factors — particularly factors V and VIII. Factor decline: Factor VIII can decline by 30–50% within 5 days of refrigerated storage. Factor V activity typically decreases more slowly but still shows a measurable drop (~20–30%). Stable factors (e.g., II, VII, IX, X) remain largely intact. Despite this, thawed plasma retains adequate coagulation activity for most clinical indications. Indications: Rapid availability in trauma, massive transfusion, or bleeding scenarios where delay is unacceptable. Routine plasma transfusions where full labile factor levels are not essential. Inventory management — hospitals often keep thawed plasma “on the shelf” to reduce wastage and provide faster turnaround. IV. Cryopoor Plasma (CPP) Cryopoor plasma is the supernatant remaining after removal of cryoprecipitate from FFP or PF24. It contains significantly reduced levels of: Fibrinogen Factor VIII von Willebrand factor Factor XIII But it retains: Factor V Factor II, VII, IX, X (the vitamin K–dependent factors) Indications: Rarely used, but may be considered in: TTP, as an exchange fluid when minimizing large multimers of vWF is desirable. Research protocols or specific institutional use cases. CPP is not routinely stocked at most hospitals and is unfamiliar to many clinicians. V. Bottom line: The plasma product you transfuse might be referred to as “FFP,” but it could be PF24 or thawed plasma. These distinctions aren’t just academic — they can affect hemostatic potential, shelf life, and even clinical utility in certain contexts. When we’re precise about plasma, we reinforce precision in practice — and help ensure the right product reaches the right patient at the right time. Next up: the historical context of FFP and current good practice for using FFP.

Some of the most meaningful things I built this year weren’t papers or presentations or new protocols. They were systems. Templates. Manuals. Scripts. Shared folders with links that worked. A “transfusion reaction holy book” with impression templates and scaffolded recommendations. An updated note template to make documentation faster and more consistent. New order sets that removed friction and reduced errors. Substantial improvements to the Excel workbook used for clinical calculations, cleaning up structure and adding missing tools. Manuals for services that had nothing—designed for fellows, by someone who had lived the gaps. And yes, the platelet script —short, sharp, and deeply satisfying to deploy. These weren’t glamorous projects. Most didn’t come with authorship or awards. But they changed things. Quietly. Steadily. Measurably. Because when you’re exhausted, overwhelmed, and still trying to learn, there’s nothing more powerful than a system that works . One that says: “Here. I’ve thought about this. I’ve built something to make it easier.” W. Edwards Deming once said, “A bad system beats a good person every time.” He was right. I’ve seen it. The smartest, kindest, hardest-working people can be flattened by broken processes. But the reverse is also true: a good system can lift people up. It can make it easier to be good at your job—even when you’re tired, new, or unsure. Medicine loves the heroic gesture—the brilliant diagnosis, the dramatic rescue, the high-impact publication. But the real work, the work that keeps the ship afloat, lives in process improvement. In clarity. In tools that actually help . I wasn’t always sure I was doing enough this year. But then I saw someone use the materials I built and say, “Oh thank god.” That’s enough for me.

This week, I handed off the call phone to a new fellow. I walked her through the MTP protocol, gave her a holy book of transfusion reactions, practiced finding HLA compatible platelets, and went over every weird little NIH-specific quirk I could think of. I gave her floaties. And now she has to jump in the pool. That’s how it works. I did everything possible to soften the landing, but eventually someone hands you the pager, and you are the one on call. You answer the consults. You make the decisions. You’re still learning—and you always will be—but suddenly the weight shifts. It’s your name on the line. This is the rhythm of medical training. You will constantly be asked to do things you don’t feel ready to do. Sometimes it feels like the system is pushing you forward too fast. Sometimes it feels like you  are holding yourself back. But every single step—from student to resident to fellow to attending—requires a quiet leap of faith. Not that you’re already good enough, but that you’re committed enough to get better. That’s what I tell the new fellows: you’re not supposed to know everything yet.  But you do  have to show up. You do  have to try. Because medicine isn’t about perfection—it’s about participation. It’s about engaging with uncertainty, asking for help when you need it, and making the best decision you can with the information you have. Floaties help. So does preparation. But the truth is, we all learn to swim the same way: by jumping in, flailing a little, and slowly figuring it out. The good news is that you’re not alone in the water. There’s a whole team behind you—faculty, colleagues, nurses, pharmacists, techs, and more—all ready to catch you if you start to sink. That’s the hidden strength of medical training. It feels like you’re doing it alone, but you never really are. And here’s the part I didn’t understand when I was the one wearing floaties: that feeling of not knowing never really goes away. But with time, you start to trust yourself more. Not because you suddenly know everything, but because you’ve seen yourself navigate uncertainty before—and come out the other side. You build confidence not in having the answers, but in your ability to find them. So jump in. You'll be okay.

In the intensive care unit, we often reach for blood tests as our window into the body’s response to critical illness. But what happens when the very tests we order begin to chip away at the patient’s ability to recover? Iatrogenic anemia—anemia caused or worsened by medical intervention, particularly diagnostic blood draws—is a well-documented but underappreciated complication of hospitalization, especially in critically ill patients. And while transfusion can be life-saving, it comes with its own risks, costs, and carbon footprint. Preventing the anemia in the first place is often safer, cheaper, and more sustainable. The Scope of the Problem In one large observational cohort from a U.S. academic medical center, critically ill patients underwent a median of 41 laboratory draws per hospitalization, with a median blood loss of 232 mL per patient—about half a unit of red cells (Luke et al., 2023). Daily losses in some ICUs approached 29 mL, and discard volumes—blood drawn but not analyzed—accounted for more than 10% of this loss. The consequences are not benign. Hemoglobin levels decline in proportion to phlebotomy intensity, and each 100 mL of blood drawn was associated with a 1.15x increase in red cell transfusion use. Patients with the highest cumulative blood loss had the lowest nadir hemoglobin values, longest hospital stays, and highest transfusion requirements. In neonatal ICU patients, the burden is even more staggering: up to 90% of circulating blood volume can be removed in the first two weeks of life alone (Widness et al., 1996). Strategies to Reduce Iatrogenic Blood Loss Patient Blood Management (PBM) strategies focus on three pillars: Optimizing anemia management Reducing iatrogenic blood loss Enhancing tolerance of anemia This post focuses on the second pillar—particularly blood-sparing techniques like: Small volume tubes (SVT) Closed blood sampling devices (CBSD) Point-of-care testing (POCT) Educational and policy interventions Bundled strategies combining the above Systematic reviews consistently show that SVT and CBSD both reduce blood draw volumes, but the data are mixed regarding their ability to reduce transfusion rates or prevent hemoglobin decline (Whitehead et al., 2019; François et al., 2022; Keogh et al., 2023). The most substantial blood conservation has been achieved through CBSD, which returns unused blood to the circuit, eliminating discard volume altogether. Yet one tool in particular—point-of-care testing—offers an especially compelling combination of blood conservation, clinical responsiveness, and workflow efficiency. Point-of-Care Testing: High Impact, Low Volume Unlike conventional lab draws, POCT uses minimal sample volumes—often 100–250 µL—and delivers results in minutes. While often framed as a convenience tool, POCT may play a crucial role in blood conservation strategies. In a NICU cohort, Madan et al. found that switching to a bedside POCT analyzer for blood gas and electrolyte testing resulted in a 46% reduction in transfusions and a 43% reduction in total transfused volume among extremely low birth weight infants (Madan et al., 2005). Notably, the frequency of testing remained unchanged, suggesting the volume savings alone made the difference. Mahieu et al. similarly observed a 48% reduction in transfusion volume among very low birth weight infants following the introduction of a POCT analyzer (Mahieu et al., 2017). Blood loss per test was significantly reduced, and the intervention was cost-saving for the national health system. In an adult ICU cohort, Salem et al. demonstrated that POCT instruments provided accurate analyte results while using only 250 µL of blood. They highlighted the role of microchemistry technology in reducing blood loss, particularly in high-acuity settings like emergency departments and operating rooms. Despite differences in study populations and methodologies, these studies converge on one key finding: POCT can reduce diagnostic blood loss and transfusion needs without compromising care. The Benefits and Risks of POCT The benefits of POCT in critical care go beyond sample volume: Faster turnaround times allow more rapid clinical decisions. Less blood drawn per test reduces the risk of phlebotomy-induced anemia. Testing at the bedside minimizes pre-analytical errors (like transport delays or sample degradation). Capillary sampling options may eliminate the need for venipuncture entirely in some cases. But there are trade-offs to consider: Differences between capillary and venous/arterial blood can affect interpretability, especially for certain analytes. Some devices have lower throughput and limited test menus compared to central labs. Repeat testing or confirmation may still be necessary, particularly for critical or unexpected values. Integration into clinical workflows—from staff training to EMR connectivity—requires planning. POCT is not a replacement for central labs, but a complementary tool. When deployed strategically—especially in high-volume testing environments like the ICU—it offers a meaningful reduction in both blood volume drawn and time to actionable data. Implementing Change: More Than Just Tubes While no single intervention prevents iatrogenic anemia on its own, the evidence supports integrating POCT and other blood-sparing strategies into routine practice, especially for ICU patients with prolonged stays or at high risk of transfusion. Barriers remain—cost, workflow adaptation, and concerns about test redundancy or accuracy—but as the data accumulate, so does the imperative to act. This is not just a patient safety issue; it’s also a sustainability issue. As one review noted, each routine lab test generates measurable carbon emissions, with full blood counts producing the equivalent of 770 meters of car travel (McAlister et al., 2022). Conclusion Iatrogenic anemia is not an inevitable side effect of ICU care—it’s a modifiable risk. By leveraging technologies like POCT, rethinking default test ordering, and aligning with PBM principles, we can reduce unnecessary blood loss, avoid transfusions, and improve outcomes for some of our sickest patients. Because sometimes, doing less really is doing more.

Introduction: When most people—doctors included—think of transfusion medicine, they picture someone approving blood products from a distance. Maybe they imagine a pathologist tucked away in the lab, rubber-stamping PRBC requests. But the reality is far more complex. Transfusion medicine physicians are clinical consultants, working at the intersection of hematology, immunology, and patient blood management. Our value lies not just in saying “yes” or “no” to transfusion, but in guiding clinicians through diagnostic uncertainty, navigating difficult cases, and improving outcomes across a wide variety of specialties. 1. A Consultative Specialty Hidden in Plain Sight Transfusion medicine isn’t a field most people choose—it’s one they discover. And when they do, they realize how central it is to patient care. TM physicians are consulted for cases that don’t fit cleanly into another box: A patient with a positive DAT and unclear hemolysis A stem cell transplant patient with febrile reactions to every unit A Jehovah’s Witness patient needing complex surgery A trauma patient with coagulopathy and no clear path forward We're brought in not just to approve blood, but to ask: Is this the right product? At the right dose? At the right time? 2. Diagnostic Expertise in Complex Cases TM consults often involve layered diagnostic reasoning. Is this hemolysis immune or non-immune? Is this thrombocytopenia ITP or drug-induced? Are we dealing with a warm autoantibody or an alloantibody in disguise? Transfusion medicine physicians integrate lab data, clinical context, and patient-specific nuances to provide recommendations that change management—not just transfusion plans, but workups, drug choices, and timelines. 3. Interdisciplinary Communication We speak many clinical dialects—cardiology, surgery, hematology, anesthesia—and translate lab findings into actionable recommendations. TM physicians regularly facilitate multidisciplinary conversations: Should we give platelets before this LP in a thrombocytopenic patient with MDS? Can we safely delay transfusion until after antibody identification? Is there a non-transfusion alternative that fits this patient’s values or goals of care? We're often the glue in communication between lab and floor, between policy and practice. 4. Blood as a Finite Resource—and a Clinical Tool Transfusion is not a benign act. Every unit carries risk: alloimmunization, TRALI, volume overload, and more. TM physicians help balance benefit and harm, especially in gray-zone cases. We advise not just on when to transfuse, but when not to: Recommending alternatives to transfusion in chronic anemia Guiding single-unit transfusion strategies Implementing PBM protocols in the ICU or OR 5. Beyond the Bedside: Policy, Quality, and Stewardship We’re also system stewards. TM physicians lead hospital transfusion committees, write massive transfusion protocols, track utilization metrics, and intervene when transfusion practices drift. Our consultative lens applies at the system level as well as the bedside. Conclusion: Transfusion medicine is not just technical—it’s clinical. Every blood product order is a clinical decision, and TM physicians are consultants in the truest sense: integrators of data, translators between teams, and advocates for safe, appropriate, patient-centered care. So next time you call the blood bank, remember: you’re not just calling to release a unit. You’re calling a consultant.

In just a few short weeks, I’ll finish fellowship. It’s not my first goodbye — far from it. But it’s the first one that might be my last. The last rotation. The last ID badge with an expiration date. The last institutional email address that will vanish the moment I step out the door. Then again, maybe not. I’ve done this enough times to know better. For the past six years, I’ve been in training. Which means I’ve also been leaving — constantly. Four major moves, three different states, countless rotations, and more logins and locker combinations than I could ever remember. Every space was temporary. Every system required re-onboarding. Every community came with an asterisk: not yours, not forever. That’s just how training works. We are a profession built on transience. You adapt quickly. You learn which bathrooms are cleanest, how to label your samples so they don’t get lost, which attendings want you to speak up and which don’t. You settle in fast, because you won’t be there long. And eventually, you learn to stop unpacking fully — not just your suitcase, but yourself. Some things I expect to miss — the bespoke patient care at the NIH. The way consults end with research questions, not billing concerns. The handful of people who made the day easier, who made you smarter without making you feel small. Other things I won’t miss at all. That’s part of it, too. But the grief that sticks with me isn’t always about the work. It’s the friendships that faded after the group chat went quiet. The cities I never really got to know. The long nights trying to decide what to throw out, because it wouldn’t fit in the moving truck. The Dresden doll from my grandmother — broken in one move. The journals I kept when I was 15 — lost in another. The people I was in those places, with those objects, doing that work — gone, or at least out of reach. I’ve spent six years learning how to leave. Sometimes gracefully, sometimes frantically, always carrying a little less than when I arrived. But for all the things I’ve lost, some things stayed. A few friendships, kept alive through effort and luck. A favorite pen. A writing ritual. The conviction that my voice matters, even in rooms that don’t expect to hear it. That’s what transition teaches you, if you pay attention: how to find meaning in borrowed space. How to build a life in 4-week blocks. How to say goodbye before it feels finished. How to carry forward what matters when most of it can’t come with you. This next move — to a faculty job, a new home, a place with no scheduled end date — is supposed to be permanent. But I’ve lived enough life in medicine to know that permanence is a story we tell ourselves to feel safe. I’ve moved too many times to believe in permanence. But I believe in showing up — even when the future is uncertain. So I’ll show up. I’ll care. I’ll build something worth keeping, even if I might have to let it go.

James is a 20-pound tabby with a big personality and, until recently, a very small urethra. A few weeks ago, he ended up in the emergency hospital with a urinary obstruction. He was stable, uncomfortable, and unimpressed. I was stressed out, sleep-deprived, and fully bracing for chaos. But the chaos never came. While James was still in the hospital, the specialty vet electronically sent detailed updates to his primary vet. When complications came up post-op, his primary vet reviewed the plan, prescribed the necessary meds, and followed through without punting anything back. Everyone seemed to know his case, take it seriously, and work together to make sure he got what he needed. It was surreal. Because somewhere between admission and discharge, I realized that my cat was getting better healthcare than I’ve ever had as a human patient. Or, honestly, even as a physician. Coordinated. Competent. Electronic. It’s hard to overstate how smoothly the logistics went during this latest hospitalization. The specialty team didn’t just say  they’d update his PCP — they did  it, electronically, before I even asked. His outpatient vet received the records in real time and acted on them. No phone tag. No “you’ll have to call them for that.” No “we don’t prescribe meds from another facility.” And it wasn’t even the first time veterinary medicine made me feel this way. Last summer, James needed a cardiac workup. He had a same-day echocardiogram, full radiologist interpretation, lab work, and a printed summary with a diagnosis and treatment plan — before we left the office . The total cost was under $1,000. That same  summer, I also needed a cardiac workup — for a new arrhythmia. It took over two months to get scheduled. I had to ask repeatedly just to find out what the test showed. And it cost nearly $10,000. Two separate systems. Two separate workups. And the only one that felt coordinated, compassionate, and efficient was the one provided to my precious fur baby. I’ve Never Been Heard Like This What I didn’t expect was how seen  I would feel throughout the process of James' hospitalization. Everyone listened. Every question was taken seriously. I wasn’t made to feel dramatic, or pushy, or irrational for advocating for my cat’s care — even when I brought up logistics, behavior changes, or subtle shifts in appetite. It hit me harder than I expected. Because I’ve spent years navigating healthcare — as a physician, as a patient, and as a caregiver. And I’ve never had this many people listen to me without needing to fight for it. Not once. Not when I brought my own symptoms to the table. Not when I managed a family member’s decline. Not when I offered clinical context as a fellow physician. It was veterinary medicine, not human medicine, that finally made me feel heard. The System Isn’t Perfect — But It Works Of course, veterinary medicine has its own barriers. Cost can be crushing. There’s no equivalent of Medicaid. There are no safety nets. But in terms of the actual delivery  of care — communication, coordination, respect — the system worked shockingly well. There was no deferral, no fragmentation, no fax-machine absurdity. There was thoughtful, consistent, and humane care. And I can’t stop thinking about it. Because if we can offer that kind of continuity and compassion to a 20-pound tabby recovering from major surgery, why is it still so hard to do the same for people? He’s Fine. I’m Grateful. And A Little Furious. James is doing great now. He had his perineal urethrostomy and bounced back without complications. His appetite is back. His fur is shiny. He’s napping aggressively in sunbeams like nothing ever happened. I, on the other hand, keep thinking about the fact that he had a smoother clinical course, a faster diagnosis, more continuity of care, and a clearer discharge plan than I’ve ever had for my own body. And I keep thinking: If my cat can have that kind of care, maybe people should too.

Extracorporeal photopheresis (ECP) is an immunomodulatory therapy increasingly used in the management of acute and chronic graft-versus-host disease (GVHD), particularly in pediatric patients for whom traditional therapies may fall short. Despite promising outcomes, pediatric ECP remains a niche practice characterized by significant variability in technique, access, safety protocols, and clinical outcomes. This post integrates insights from two comprehensive reviews to explore practical and clinical aspects of pediatric ECP, combining real-world experience with calls for standardization and research. 1. What is ECP and How Does it Work? ECP is a cellular therapy involving: Leukapheresis  to collect white blood cells (WBCs) Incubation  with 8-methoxypsoralen (8-MOP), a photosensitizer Exposure to UVA light Reinfusion  of the treated WBCs into the patient This process is thought to promote immune tolerance by shifting immune responses from inflammatory (Th1) to regulatory (Th2) profiles, inducing apoptosis of pro-inflammatory cells, and increasing regulatory T-cell populations. While the exact mechanism in GVHD remains unclear, multiple pathways including cytokine modulation, monocyte differentiation, and B-cell regulation have been implicated. 2. ECP Systems: In-Line vs. Off-Line Feature In-Line (UVAR XTS, CELLEX) Off-Line (COBE Spectra, COM.TEC, etc.) System Type Closed, automated Open, manual Leukapheresis & Irradiation Integrated Performed on separate devices Flow Type Discontinuous (XTS) / Continuous (CELLEX) Continuous preferred Extracorporeal Volume (EV) XTS: up to 480 mL, CELLEX: ~216–266 mL Variable (lowest: COM.TEC at 137 mL) Continuous flow systems yield more mononuclear cells (MNCs) and reduce EV, making them preferable for pediatric use. 3. Indications and Clinical Outcomes in Pediatrics In children, ECP is primarily used for: Steroid-refractory acute GVHD : response rates 50–100%, depending on organ involvement Chronic GVHD : ~60% response rate; enables steroid tapering However, all current data come from case series or observational studies— no randomized controlled trials (RCTs)  have included patients under 17 years. While adult RCTs suggest efficacy, extrapolation to pediatrics requires caution. 4. Technical and Clinical Challenges A. Extracorporeal Volume (EV) High EV can cause hypotension and hemodynamic instability in low-weight children. Strategies to minimize risk: Use lower-EV devices (e.g., CELLEX, COM.TEC) Prime circuit with red blood cells (RBCs) or 5% albumin Administer saline or albumin boluses pre-procedure Device EV (mL) Min. Weight Recommendations UVAR XTS 480 >40 kg (with priming) CELLEX 216–266 >30 kg (without priming) COM.TEC 137 <30 kg (with priming preferred) B. Vascular Access Central venous catheters (single- or double-lumen) are commonly used Catheter-related infections and occlusions are the most frequent complications Reported Complication Rates: Infections: 3.7–7% Occlusion: ~4% Preventive measures: urokinase/tPA, aseptic technique, dedicated central lines C. Hematologic and Metabolic Considerations ECP can cause modest drops in hematologic parameters: Hemoglobin: median drop of 1.5 g/dL Platelets: median drop of 17% Typical Pre-Procedural Lab Cutoffs: Parameter Threshold Hematocrit >24–28% Platelet count >20,000–50,000/µL WBC count >1,000/µL There is no consensus on ideal target cell yields or on correlation between infused MNC counts and clinical efficacy. 5. Scheduling and Duration of Therapy Protocols vary widely: Initial Phase:  2–3 treatments/week Maintenance:  Decrease to every 2–4 weeks based on response GVHD Monitoring:  Weekly for aGVHD, every 1–2 months for cGVHD Study Initial Schedule Tapering Kanold 3x/week for 3 weeks Gradual taper Messina 2x/week for 1 month, biweekly for 2 months Then monthly for 3+ months Foss No difference found between 1x vs 2x/week Schedules individualized There is no evidence that more intensive schedules yield better outcomes. 6. Alternative Techniques: Mini Buffy Coat ECP For children who cannot tolerate leukapheresis: Mini buffy coat method  involves collecting 100–200 mL of whole blood Buffy coat is prepared and irradiated in a closed system Red cells, plasma, and platelets are returned to the patient Clinical Results: 84% response rate in pediatric aGVHD Strong correlation between higher WBC dose/kg and response This technique may be a valuable alternative in patients <20 kg. 7. Gaps in Knowledge and Recommendations Despite widespread clinical use, pediatric ECP suffers from a lack of standardization and rigorous evidence. Key areas needing further research include: Domain Current Gaps Recommendations Patient selection No consensus on minimum weight or lab cutoffs Develop evidence-based eligibility guidelines Product evaluation No QC benchmarks or ideal cell dose/kg Define and validate efficacy markers Anticoagulation protocols Heparin vs. citrate strategies vary by center Standardize anticoagulation practices based on risk Scheduling Highly variable schedules Conduct studies comparing intensive vs. tapered regimens Vascular access Complications common Guidelines for catheter type and maintenance Alternative collection methods Mini ECP underutilized Further evaluate in RCTs or multicenter trials 8. Conclusion ECP is a safe, well-tolerated, and potentially effective treatment for pediatric GVHD, particularly in steroid-refractory cases. However, practice varies widely, and most evidence is derived from observational data. To expand safe access and improve outcomes, standardized protocols and prospective studies—especially randomized trials in pediatric populations—are urgently needed. Until then, successful ECP in children will continue to rely on experienced multidisciplinary teams, careful patient selection, and vigilant monitoring. Have experience with pediatric ECP in your institution? Let us know what’s working—and what’s not. References DeSimone RA, Schwartz J, Schneiderman J. Extracorporeal photopheresis in pediatric patients: Practical and technical considerations. J Clin Apher. 2017; 32: 543–552. https://doi.org/10.1002/jca.21534 Sniecinski, I., & Seghatchian, J. (2017). Factual reflections and recommendations on extracorporeal photopheresis in pediatrics. Transfusion and Apheresis Science , 56 (2), 118-122. https://doi.org/10.1016/j.transci.2017.03.013Get rights and content

Introduction Most blood donors walk out of the collection center with little more than a bandage and a juice box. But for a small subset, the donation experience can be complicated by physiologic reactions—ranging from mild lightheadedness to full-blown syncope. These events, often referred to as “donor reactions,” are typically benign and self-limited, but they matter. For transfusion medicine physicians and trainees, recognizing and managing these reactions is critical—not just for donor safety, but for maintaining public trust in the blood supply. This post outlines the most common donor reactions, their mechanisms, risk factors, and management strategies, with a focus on practical relevance for pathology residents and fellows rotating through transfusion medicine. What Is a Donor Reaction? A donor reaction refers to any adverse response experienced by a blood donor during or shortly after donation. While most are mild, some can be alarming or—rarely—require clinical intervention. Reactions are classified by physiologic mechanism (e.g., vasovagal, mechanical, or citrate-related) and by severity (mild, moderate, or severe). Understanding how to identify, manage, and prevent these events is essential for ensuring a safe and positive donation experience. The Most Common Reactions Vasovagal Reactions These are the most common donor reactions and are caused by increased vagal tone, leading to transient hypotension and bradycardia. Clinical features include: Lightheadedness, dizziness, visual changes Nausea Sweating, pallor Syncope—with or without convulsions , which can be brief and non-epileptic but very alarming Management: Prompt recognition of prodrome Supine positioning with legs elevated Cold compresses to face and neck Reassurance and quiet environment Monitor until symptoms resolve Syncope is more common in: First-time donors Younger donors (particularly adolescents) Female donors , likely due to a combination of physiologic and psychosocial factors Donors with low blood volume or anxiety Hematoma Formation and Bruising Occurs when blood leaks from the vein into surrounding tissue, often from a partial needle dislodgement or inadequate compression post-donation. Management: Immediate removal of needle if infiltration occurs Apply firm pressure until bleeding stops Cold compresses in the first 24 hours; warm compresses afterward Pressure dressing  for larger hematomas Documentation and follow-up if significant Citrate Reaction (Apheresis Only) Due to systemic binding of ionized calcium by citrate anticoagulant: Perioral or fingertip tingling Muscle cramping Nausea Metallic taste Rarely, severe symptoms like tetany or arrhythmias Management: Oral calcium supplementation Slowing the ACD infusion rate Intravenous calcium in rare severe cases Nausea and Vomiting May overlap with vasovagal symptoms or occur due to anxiety, dehydration, or prolonged fasting. Management: Supine positioning Fluids and rest Discreet handling and privacy for emesis events Delayed Reactions Some donors feel dizzy or fatigued hours later, especially if they resume vigorous activity too soon. Management: Education at time of donation: hydration, rest, activity restrictions Provide emergency contact if symptoms worsen Less Common but Important Reactions Nerve Irritation or Injury Direct trauma or compression of adjacent nerves (e.g., median or cutaneous nerves) may result in: Shooting or radiating pain during phlebotomy Persistent numbness, tingling, or weakness Management: Immediate needle removal if pain occurs Documentation and donor follow-up Referral to occupational health if symptoms persist Arterial Puncture Rare but potentially serious complication when an artery is inadvertently accessed instead of a vein. Signs: Rapid filling of collection bag Bright red, pulsatile blood High pressure flow into the tubing Hematoma formation at site Management: Immediate cessation of collection Remove needle and apply firm, prolonged pressure  (at least 10 minutes) Use a pressure dressing Document and advise donor to seek care for signs of compartment syndrome or neurologic deficits Who's at Risk? Certain donor profiles consistently show higher rates of adverse reactions. First-time donors  are especially vulnerable due to unfamiliarity, needle anxiety, or fear of the process. Adolescents and young adults —particularly female donors —also experience higher rates of vasovagal syncope, likely due to heightened autonomic reactivity and lower circulating blood volume. Add dehydration, low BMI, or a skipped meal, and the risk rises further. A quick pre-donation conversation can go a long way: asking about prior reactions, encouraging hydration, and recognizing nervous body language are simple, high-yield interventions for anticipating and reducing reactions. Prevention and Mitigation Strategies Donor safety starts before the needle is even placed. Encourage donors to hydrate and eat beforehand, and offer a salty snack to expand plasma volume. For apheresis donors, provide oral calcium to prevent citrate-related symptoms. During collection, reclined positioning and attentive monitoring are key. Early signs of a vasovagal reaction—yawning, pallor, sweating—should prompt immediate action: stop the draw, recline the donor, apply cold compresses, and offer reassurance. Most syncopal episodes resolve quickly with these measures. Post-donation, ensure donors rest briefly, hydrate, and receive clear instructions about avoiding strenuous activity. Empathetic handling of reactions reinforces trust and can turn even a rocky first donation into a repeat experience. Why It Matters Donor reactions are not just operational issues—they are clinical events that influence public trust in the blood supply. Even minor reactions can deter repeat donation. As pathology residents and fellows, you may be called on to evaluate donor events, participate in root cause analysis, or improve donor screening and safety protocols. Your ability to understand and address these events directly impacts donor retention and transfusion system integrity. Final Thoughts Common donor reactions are rarely dangerous but deserve careful attention. Early recognition, effective management, and thorough documentation help keep donors safe and confident in the system. From a minor faint to a hematoma to a rare arterial puncture, every reaction is an opportunity to improve our systems—and to advocate for those whose generosity makes transfusion possible.

Warm autoantibodies (WAAs) are one of the most conceptually strange and serologically compelling phenomena in transfusion medicine. They break all the rules. And a recent case reminded me just how much art is involved in managing them—even when the science is sound. The patient was an older adult with newly identified anemia. The indirect antiglobulin test (IAT) was strongly panreactive at 4+. The direct antiglobulin test (DAT) lit up too—4+ with polyspecific antihuman globulin and anti-IgG, but negative with anti-C3. There were signs of hemolysis: elevated LDH and indirect bilirubin, downtrending haptoglobin. But the serum remained visually clear—no hemoglobinemia. Just a steady, smoldering hemolytic process consistent with warm autoimmune hemolytic anemia (WAIHA). Warm autoantibodies, as a reminder, are IgG antibodies directed against “self” antigens on red blood cells. They react best at 37°C—hence the name—and often appear as panagglutinins, reacting with all red cells regardless of antigen profile. While their specificity is typically undefined, they occasionally show preferential reactivity against Rh system antigens, especially RhD. But more often than not, the pattern is messy and nonspecific. What’s fascinating is that despite this overwhelming in vitro reactivity, patients with WAAs— even those with active hemolysis like mine —can often tolerate allogeneic transfusion just fine. That paradox is what makes WAAs so serologically intriguing and clinically humbling. The Practical Challenges of WAAs Rule Out Alloantibodies & Choose the Right Blood: The first priority is identifying any additional  alloantibodies that might be hiding beneath the autoantibody. This can require special techniques like autoadsorption or “saline AHG” testing that dampen WAA reactivity while preserving alloantibody detection. Once that’s done, most institutions provide ABO- and Rh-compatible units and match for Rh and Kell antigens the patient lacks to reduce future alloimmunization. There’s no universal standard for how far to take matching, but Rh/Kell coverage is a common and practical middle ground. Overlook the Incompatible Crossmatch—Sort Of: After all that, the crossmatch will almost always remain incompatible. And that’s okay. The phrase “least incompatible unit” gets tossed around a lot, but it’s not a guarantee of safety—just a shorthand for “we did our due diligence.” In truth, no serologic grading system has been validated to predict transfusion success in WAA cases. The unit that gives a 1+ reaction doesn’t necessarily survive better than one that’s 3+. What matters is clinical judgment and communication. Communicate Clearly with Clinicians: A DAT-positive patient, a fully incompatible crossmatch, and ongoing hemolysis can sound like a disaster to non-hematology clinicians. It’s our job to demystify that. I find myself saying this often: Yes, it looks scary on paper. But we’ve ruled out alloantibodies, chosen appropriate antigen-negative blood, and transfusion is still safe and appropriate when clinically indicated.  Avoid empty reassurances. Focus on shared decision-making. A Clinical Balancing Act WAAs can drive clinically significant hemolysis of the patient’s own red cells, and on occasion transfused donor cells. But not always, and paradoxically WAAs can sometimes spare donor cells while destroying native cells. That variability is part of what makes these antibodies so clinically fascinating. In vitro, they react with everything. In vivo, their effects exist on a spectrum—from silent bystanders to active participants in hemolysis. Managing WAAs is a constant balancing act. It requires knowing when to move forward despite serologic incompatibility, and when to stop and reassess. It demands vigilance, nuance, and collaboration. These antibodies force us to think beyond the test tube and remember that in transfusion medicine, the right answer is rarely just a result—it’s a decision.

When a patient refuses a blood transfusion, many clinicians feel backed into a corner. Sometimes, that refusal stems from deeply held religious beliefs—most notably among Jehovah’s Witnesses, who typically decline whole blood and its primary components. But here's the truth: refusing transfusion doesn’t mean refusing care. It means we need to be better stewards of everything else we have. 🔄 From “No” to “Now What?” Too often, the conversation stops at “They won’t accept blood.” But clinically, the more urgent question is: what can we offer instead? Fortunately, there’s a growing arsenal of strategies—many pioneered in response to transfusion refusal—that improve outcomes across the board. And the data backs that up. 💉 Bloodless Cardiac Surgery: The Data Consider cardiac surgery, one of the most transfusion-intensive fields in modern medicine. In a 10-year retrospective study of 91 Jehovah’s Witness patients undergoing cardiac procedures at a single institution, in-hospital mortality was just 5.5%, with outcomes for isolated coronary artery bypass grafting (CABG) and aortic valve replacement (AVR) falling within the 95% confidence intervals of Society of Thoracic Surgeons (STS) risk model predictions. Major complications—including reoperation, sepsis, stroke, and dialysis—remained low, and results were consistent across both elective and urgent surgeries.¹ These findings are echoed in a 2024 meta-analysis of 10 studies involving 780 Jehovah’s Witnesses and 1,182 non-Witness controls undergoing cardiac surgery. Despite 86% of non-Witness patients receiving at least one transfusion, there was no significant difference in perioperative mortality (OR 0.91; 95% CI, 0.55–1.52; p = 0.72). Jehovah’s Witnesses had less total blood loss (p = 0.001), and both pre- and postoperative hemoglobin levels were significantly higher.² In short: bloodless cardiac surgery is not only possible—it’s safe, when care is proactive and deliberate. 🧬 Blood Products and the Nuance of Refusal To care well for patients who decline transfusion, we need more than clinical tools—we need clarity. Here's the breakdown: Whole Blood Contains all components: red cells, white cells, plasma, and platelets. Jehovah’s Witnesses universally reject transfusion of whole blood. Primary Components Directly separated from whole blood. These are typically not accepted. Red blood cells Plasma Platelets White blood cells Secondary Components (Blood Derivatives) Created by further processing or fractionating blood components. Some Jehovah’s Witnesses accept these products, depending on individual beliefs and local congregation guidance. Albumin Immunoglobulins Coagulation factor concentrates Cryoprecipitate Autologous vs. Allogeneic Transfusion Allogeneic: from a donor—generally not accepted. Autologous: from the patient’s own circulation—may be accepted if done through a closed-loop system (e.g., cell salvage). This is why personalized planning and transparent communication are essential. Always clarify what the patient will or won’t accept—because individual preferences can vary dramatically within the community. 🛠️ What It Takes to Do Bloodless Medicine Well The best outcomes don’t come from avoiding transfusion—they come from deliberate patient blood management (PBM). Many of the tools that support JW patients improve care systemwide. Preoperative Optimization Iron, B12, and folate supplementation Erythropoiesis-stimulating agents Minimizing iatrogenic blood loss Intraoperative Precision TXA and other antifibrinolytics Meticulous surgical technique Cell salvage (when acceptable) Postoperative Support Tolerance of lower Hgb thresholds Oxygen and volume support Strategies to support marrow recovery 💡 What This Teaches Us Caring for patients who decline transfusion isn’t a constraint—it’s a clinical and ethical opportunity. It pushes us to: Communicate better Plan ahead Treat each patient as a partner in care And above all, it reminds us that the safest blood is the unit we never have to give. 📚 References Jassar AS, Makar M, Pullins E, et al. Cardiac Surgery in Jehovah’s Witness Patients: Ten-Year Experience. Ann Thorac Surg.  2012;93(1):19–25. doi:10.1016/j.athoracsur.2011.07.076 Gemelli M, Italiano EG, Geatti V, et al. Optimizing Safety and Success: The Advantages of Bloodless Cardiac Surgery. A Systematic Review and Meta-Analysis of Outcomes in Jehovah’s Witnesses. Curr Probl Cardiol.  2024;49(1, Part B):102078. doi: 10.1016/j.cpcardiol.2023.102078

I plugged in the numbers—height, weight, sex—and the algorithm spit out a total blood volume of 8 liters. Eight liters. That’s more than the average adult elephant. Okay, not really—but it was definitely more than was physiologically plausible for the patient in front of me. On paper, the formula worked. In practice, it made no sense. And that’s the quiet danger of laboratory standardization: the illusion of precision without the reality of accuracy. Algorithms, equations, and scoring systems are everywhere in lab medicine. We use them to estimate total blood volume, calculate corrected count increments, determine transfusion thresholds, risk-stratify patients, and more. They are essential. They are powerful. And they are, too often, blindly applied. Because we’ve come to equate “standardized” with “valid,” even when the standard was built on shaky ground. The Allure—and Illusion—of the Standard Standardization is the bedrock of laboratory medicine. It’s what lets us compare results across institutions, apply clinical guidelines, and run multicenter trials. Without it, evidence-based medicine would fall apart. But standardization is only as good as the data and assumptions it rests on. And in lab medicine, those assumptions are rarely neutral. When you dig into where these formulas come from—whether it’s Nadler’s formula for TBV, the use of sex-specific reference ranges, or scoring systems for conditions like heparin-induced thrombocytopenia or DIC—you often find something surprising: a very narrow foundation. Many of these tools were derived from datasets that are small, homogeneous, and unrepresentative of the patients we see today. And once a tool is canonized—once it makes it into the LIS, into the protocol, into the reference manual—it becomes difficult to question. But we should. Where Bias Hides in Plain Sight Bias in lab medicine isn’t always dramatic. Sometimes, it’s a small nudge—enough to make a test look slightly more normal than it should, or an algorithm overshoot the mark. But when scaled across thousands of patients, those nudges matter. 🧮 Biased Formulas Take total blood volume. Nadler’s formula is widely used and appears straightforward: plug in height, weight, and sex, and out comes a number. But Nadler’s equation was derived from a limited sample of healthy individuals in the 1960s—primarily white, young, and lean. Apply that formula to a patient with obesity or fluid retention, and you may end up drastically misestimating their TBV. That misestimation can lead to inappropriate collection during apheresis procedures. 📉 Reference Intervals We treat reference intervals as facts, but they’re often closer to educated guesses—highly dependent on the population used to derive them. Hemoglobin and creatinine reference ranges, for instance, are typically stratified by sex assigned at birth, but this binary stratification fails to reflect the diversity of physiologic reality. Patients on hormone therapy, those with chronic conditions, or those with differing muscle mass may fall outside “normal” ranges while being perfectly healthy—or may be misclassified because the ranges were never built with them in mind. Even more problematic, many intervals were never validated in pediatric, geriatric, or racially diverse populations. And yet these ranges shape everything: decisions to transfuse, to screen further, to diagnose. The reference range becomes the gatekeeper to clinical action—even when it shouldn't be. 📊 Risk Scores Scoring systems like the 4Ts for HIT or the ISTH DIC score assume access to certain labs, follow certain clinical patterns, and reward conformity. They can underperform in patients with atypical presentations or resource-limited settings. 🤖 Machine Learning and AI Even newer tools aren’t immune. Predictive models built from EHR data can reflect and amplify existing disparities—especially if the training data skews toward certain populations or omits key variables like socioeconomic status, language access, or prior healthcare usage. Bias doesn’t just live in the past—it gets encoded into the future. The Cost of “Close Enough” We love numbers in the lab. But “close enough” doesn’t cut it when you’re estimating blood volume for a patient with reduced muscle volume, or when a scoring tool steers you away from a diagnosis you should  be considering. Small inaccuracies in algorithms can lead to real-world consequences: missed diagnoses, under-treatment, over-transfusion, delayed care. And the worst part? These errors often go unrecognized—because the numbers looked clean, the boxes were checked, the equation was “standard.” Toward Better, Fairer Standardization So what do we do? We start by asking better questions: Who was this algorithm validated on? What assumptions does it make? Where does it fail? How does it perform in patients who don’t look like the “standard”? We need laboratory professionals involved not just in implementing tools, but in designing and validating them. We need to stop treating standardization as a destination and start treating it as a continuous process—one that requires transparency, adaptability, and humility. And most of all, we need to resist the seduction of certainty. Algorithms can guide us, but they can’t replace judgment. The Patient Didn't Have 8 Liters That patient didn’t have 8 liters of blood. But the algorithm said they did—and if we hadn’t caught it, we might have used that number to justify unsafe collection volumes. That’s the danger: when standardized tools are treated as facts, patients bear the consequences. Because in the end, the algorithm was wrong. And we knew better.